Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

QVA149 Articles

Positive new data on Novartis' once-daily QVA149 in COPD patients

23 April 2013

Forest launches COPD product Tudorza in USA

12 December 2012

News briefs: Italy lifts hold on Novartis vaccines; files for QVA149 in Japan; Mylan patent settlement

11 November 2012

Novartis/Vectura's QVA149 is filed as a treatment for COPD in Europe; Certican EU approval

26 October 2012

New data from Novartis on QVA149 and Seebri Breezhaler at ERS

3 September 2012

Novartis set to file QVA149 filing in EU and Japan by end of year

31 August 2012

Credit Suisse focus on new drugs for COPD

19 August 2012

Showing 1-7 of 7 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Elan makes "transformational" acquisitions and a divestment
  • Is failure to adopt business process management putting the pharma industry at risk?
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Elan makes "transformational" acquisitions and a divestment

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS